PARP1 and head and neck squamous cell carcinoma: We reported that PARP1 inhibitors enhance the therapeutic ratio achieved by radiotherapy by interfering with the replication elongation for the HR-deficient head and neck squamous cell carcinoma (HNSCC) cell lines [33].